For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

Group newsletter: CCTG Connection

Archived Bulletins

September 23, 2020

The Canadian Cancer Trials Group (CCTG) is pleased to announce that our Director, Dr. Janet Dancey, has been elected to the Canadian Academy of Health Sciences (CAHS), which represents Canadian health sciences internationally and informs solutions that improve the health of all Canadians.

Read More

Published: September 23, 2020
Category: Publications

Publication for BL12: A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients with Advanced Urothelial Cancer Progressing on or after a Platinum Containing Regimen

Read More

Published: September 23, 2020
Category: Publications

The results for the CCTG PA7 trial were recently presented at the European Society for Medical Oncology (ESMO) virtual Congress. The CCTG lead for this study, Dr. Daniel Renouf, reported on key results of the PA7 Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma Randomized Phase II Study of Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) vs. GEM, Nab-P, Durvalumab (D) and Tremelimumab (T) as First Line study.

Read More

Published: September 23, 2020
Category: Other
Dr. Libni Joseph Eapen passing

CCTG would like to extend condolences to the family, friends, and colleagues of Dr. Libni Joseph Eapen who passed suddenly last week.  Dr. Eapen was a researcher and radiation oncologist at the Ottawa Cancer Centre for the entirety of his career, he dedicated his 66 years to learning, teaching, humour and healing.

Condolences can be left on his obituary page https://www.dignitymemorial.com/obituaries/ottawa-on/libni-eapen-9358605

Read More

September 09, 2020

Published: September 09, 2020
Category: Trials
Trial Activation: BRC8

BRC8 MRI Brain Surveillance Alone versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)" has been centrally activated.

Read More

The Phase 2 clinical trial will analyze blood-based biomarkers versus conventional radiography for cancer patients treated with immunotherapy; findings could change direction of lung cancer treatment

Read More

Published: September 09, 2020
Category: Publications
Publications: OV19 JBR10 MAP3 CE6 and BR18
  • OV19: A Randomized, Two-Arm, Multi-Centre Gynecologic Cancer Intergroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) In Patients with Epithelial Ovarian Cancer
  • JBR10: Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10
  • MAP3: A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
  • CE6: A Randomized Phase III Study Of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients
  • BR18: A Phase II/III Double Blind Randomized Trial of BMS-275291 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of
    Advanced or Metastatic Non-Small Cell Lung Cancer
Read More

July 15, 2020

Published: July 15, 2020
Category: CCTG Bulletin

CCTG investigators are contributing to COVID-19 research by developing and leading innovative, cutting-edge clinical trials to support patients with cancer.

Read More